Frans Van de Werf
Werf, Frans van de
Van de Werf, F. (Frans)
VIAF ID: 77741412 (Personal)
Permalink: http://viaf.org/viaf/77741412
Preferred Forms
- 100 0 _ ‡a Frans Van de Werf
-
-
- 100 1 _ ‡a Werf, Frans van de
- 100 1 _ ‡a Werf, Frans van de
4xx's: Alternate Name Forms (5)
Works
Title | Sources |
---|---|
Cardiologie | |
ESC Congress 2003: abstracts | |
Fourth universal definition of myocardial infarction | |
The genesis of the third heart sound, 1982: | |
Impact of In-Hospital Revascularization on Survival in Patients With Non–ST-Elevation Acute Coronary Syndrome and Congestive Heart Failure | |
Impact of TIMI 3 patency before primary percutaneous coronary intervention for ST-elevation myocardial infarction on clinical outcome: results from the ASSENT-4 PCI study | |
Improved regional function after autologous bone marrow-derived stem cell transfer in patients with acute myocardial infarction: a randomized, double-blind strain rate imaging study | |
Improving public health by improving clinical trial guidelines and their application | |
Increased cardiac expression of tissue inhibitor of metalloproteinase-1 and tissue inhibitor of metalloproteinase-2 is related to cardiac fibrosis and dysfunction in the chronic pressure-overloaded human heart | |
Increased Expression of Syndecan-1 Protects Against Cardiac Dilatation and Dysfunction After Myocardial Infarction | |
Influence of rs5065 atrial natriuretic peptide gene variant on coronary artery disease. | |
Inhibition of urokinase-type plasminogen activator or matrix metalloproteinases prevents cardiac injury and dysfunction during viral myocarditis | |
Inhibitors of the platelet thrombin receptor: will they live up to their promises? | |
International differences in in-hospital revascularization and outcomes following acute myocardial infarction A multilevel analysis of patients in ASSENT-2 | |
International variation in invasive care of the elderly with acute coronary syndromes. | |
Intraluminal Thrombus in Facilitated Versus Primary Percutaneous Coronary Intervention | |
Inventory of European databases related to cardiovascular diseases | |
Keeping patients safe while avoiding bias in randomised trials | |
Lack of Concordance Between Local Investigators, Angiographic Core Laboratory, and Clinical Event Committee in the Assessment of Stent Thrombosis: Results From the TRACER Angiographic Substudy | |
Large streamlined trials in cardiovascular disease | |
Left-to-right shunting in common congenital heart defects: which patients are eligible for percutaneous interventions? | |
Letter by Van de Werf et al Regarding Article, “Using Dabigatran in Patients With Stroke: A Practical Guide for Clinicians” | |
Long-term follow-up results of tilt training therapy in patients with recurrent neurocardiogenic syncope | |
Long-term outcomes of left bundle branch block in high-risk survivors of acute myocardial infarction: The VALIANT experience | |
Management and outcomes of patients presenting with STEMI by use of chronic oral anticoagulation: results from the GRACE registry | |
[Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation] | |
Matricellular proteins and matrix metalloproteinases mark the inflammatory and fibrotic response in human cardiac allograft rejection | |
Medication performance measures and mortality following acute coronary syndromes | |
Migration of two venous stents into the right ventricle in a patient with May-Thurner syndrome. | |
Mind the model: effect of instrumentation on inducibility of atrial fibrillation in a sheep model | |
Mortality at 1 year with combination platelet glycoprotein IIb/IIIa inhibition and reduced-dose fibrinolytic therapy vs conventional fibrinolytic therapy for acute myocardial infarction: GUSTO V randomized trial | |
Myocardial infarction following coronary artery bypass graft surgery increases healthcare resource utilization | |
Nitric oxide inhalation improves microvascular flow and decreases infarction size after myocardial ischemia and reperfusion. | |
Non-ST-segment elevation acute coronary syndrome in patients with renal dysfunction: benefit of low-molecular-weight heparin alone or with glycoprotein IIb/IIIa inhibitors on outcomes. The Global Registry of Acute Coronary Events | |
Outcome of ST-elevation myocardial infarction treated with thrombolysis in the unselected population is vastly different from samples of eligible patients in a large-scale clinical trial | |
Outcome of urgent and elective percutaneous coronary interventions after pharmacologic reperfusion with tenecteplase combined with unfractionated heparin, enoxaparin, or abciximab | |
Outcomes among non-ST-segment elevation acute coronary syndromes patients with no angiographically obstructive coronary artery disease: observations from 37,101 patients | |
Outcomes from patients with multi-vessel disease following primary PCI: staged PCI imparts very low mortality | |
Outcomes of a pharmacoinvasive strategy for successful versus failed fibrinolysis and primary percutaneous intervention in acute myocardial infarction | |
Overexpression of a constitutively active protein kinase G mutant reduces neointima formation and in-stent restenosis | |
Troponin T and quantitative ST-segment depression offer complementary prognostic information in the risk stratification of acute coronary syndrome patients | |
Underestimated and under-recognized: the late consequences of acute coronary syndrome (GRACE UK-Belgian Study). | |
Unexplained international differences in clinical outcomes after acute myocardial infarction and fibrinolytic therapy: lessons from the Hirulog and Early Reperfusion or Occlusion (HERO)-2 trial | |
Upstream Clopidogrel Use and the Efficacy and Safety of Early Eptifibatide Treatment in Patients With Acute Coronary Syndrome | |
Use of a tacrolimus-eluting stent to inhibit neointimal hyperplasia in a porcine coronary model. | |
Use of evidence-based medicine for acute coronary syndromes in the elderly and very elderly: insights from the Sibrafiban vs aspirin to Yield Maximum Protection from ischemic Heart events postacute cOroNary sYndromes trials | |
Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both | |
VALsartan In Acute myocardial iNfarcTion (VALIANT) trial: baseline characteristics in context | |
Values for Mitral Valve Annulus Dimensions in Normals and Patients with Mitral Regurgitation | |
A variant at chromosome 9p21 is associated with recurrent myocardial infarction and cardiac death after acute coronary syndrome: the GRACE Genetics Study | |
Variations in pre-hospital fibrinolysis process of care: insights from the Assessment of the Safety and Efficacy of a New Thrombolytic 3 Plus international acute myocardial infarction pre-hospital care survey | |
Vorapaxar, a platelet thrombin-receptor antagonist, in medically managed patients with non-ST-segment elevation acute coronary syndrome: results from the TRACER trial. | |
Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2°P-TIMI 50 trial | |
Warfarin use and outcomes in patients with atrial fibrillation complicating acute coronary syndromes | |
What is the frequency and functional and clinical significance of complex lesions in non–infarct-related arteries after fibrinolysis for acute ST-elevation myocardial infarction? |